Printer Friendly

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017.

[ClickPress, Mon Jul 01 2013] The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.

The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201(Tl-201), gallium-67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The PET radioisotopes market is dominated by fluoride-18 (F-18), followed by rubidium-82 (Rb-82).

Full Report Details at


Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters has not been arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131(I-131), which is poised to grow at a CAGR of 7.7% from 2012 to 2017. The Asia-Pacific market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin's lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192).

Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are boosting the growth of the Asia-Pacific nuclear medicine market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The nuclear disaster at Fukushima nuclear plants in 2011 had a major impact on radioisotope production in Japan, which is the largest consumer market in the Asia-Pacific region. The Asia-Pacific region is insulated from the global crisis in Mo-99 supply since the production is based on local nuclear plants and OPAL reactor of ANSTO. ANSTO is deemed as the future solution to compensate global Mo-99 demand.

Major players in the radiopharmaceuticals market are Nihon Medi-Physics Co., Ltd. (Japan), Covidien PLC (U.S.), Fujifilm Corporation (Japan), ANSTO (Australia), and IBA S.A (Belgium).

The Asia-Pacific stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The Asia-Pacific stable isotopes market was estimated at $56.1 million in 2012 and is expected to cross $100.0 million by 2017 at a CAGR of 12.6%.

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Sigma Aldrich (U.S.) in 2012.

Scope of the Report

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017

- Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Global Trends & Forecast to 2017

- European Nuclear Medicine / Radiopharmaceuticals Market & Stable Isotopes - Global Trends & Forecast to 2017

- Radiation Detection, Monitoring & Safety Market (Geiger Counter, Ionization Chamber, Scintillator, Terahertz detector, Dosimeter, Environment Monitor, Shield, Lead Apron, Eyewear & Glove) - Competitive Analysis & Global Forecasts to 2017

Copyright 2013 ClickPress

Provided by an company
COPYRIGHT 2013 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Article Type:Industry overview
Geographic Code:90ASI
Date:Jul 1, 2013
Previous Article:Market Report, "Russia Insurance Report Q3 2013", published.
Next Article:Recently released market study: PharmaPoint: Hepatitis C Virus - Current and Future Players.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters